Peripheral immune responses to filoviruses in a reservoir versus spillover hosts reveal transcriptional correlates of disease

Front Immunol. 2024 Jan 8:14:1306501. doi: 10.3389/fimmu.2023.1306501. eCollection 2023.

Abstract

Several filoviruses, including Marburg virus (MARV), cause severe disease in humans and nonhuman primates (NHPs). However, the Egyptian rousette bat (ERB, Rousettus aegyptiacus), the only known MARV reservoir, shows no overt illness upon natural or experimental infection, which, like other bat hosts of zoonoses, is due to well-adapted, likely species-specific immune features. Despite advances in understanding reservoir immune responses to filoviruses, ERB peripheral blood responses to MARV and how they compare to those of diseased filovirus-infected spillover hosts remain ill-defined. We thus conducted a longitudinal analysis of ERB blood gene responses during acute MARV infection. These data were then contrasted with a compilation of published primate blood response studies to elucidate gene correlates of filovirus protection versus disease. Our work expands on previous findings in MARV-infected ERBs by supporting both host resistance and disease tolerance mechanisms, offers insight into the peripheral immunocellular repertoire during infection, and provides the most direct known cross-examination between reservoir and spillover hosts of the most prevalently-regulated response genes, pathways and activities associated with differences in filovirus pathogenesis and pathogenicity.

Keywords: Marburg virus; bats; comparative analysis; correlates of disease; filovirus; immune response; spillover host; viral reservoir.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chiroptera*
  • Filoviridae* / genetics
  • Humans
  • Immune Tolerance
  • Immunity
  • Marburgvirus*

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was partially funded by DTRA grant HDTRA1-14-1-0016. Additional support was also provided by CDC and RKI.